Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

@article{Cuzick2011PrognosticVO,
  title={Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.},
  author={J. Cuzick and M. Dowsett and Silvia Pineda and C. Wale and J. Salter and E. Quinn and L. Zabaglo and E. Mallon and A. R. Green and I. Ellis and A. Howell and A. Buzdar and J. Forbes},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 32},
  pages={
          4273-8
        }
}
  • J. Cuzick, M. Dowsett, +10 authors J. Forbes
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant recurrence beyond that obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, endocrine treatment) in women with early breast cancer, confirming earlier reports. The aim of this article is to determine how much of this information is contained in standard immunohistochemical (IHC) markers. PATIENTS AND… Expand
579 Citations
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
  • M. Dowsett, I. Sestak, +7 authors J. Cuzick
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
  • 463
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
  • M. Dowsett, J. Cuzick, +11 authors S. Shak
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
  • 570
  • PDF
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
  • S. Paik, G. Tang, +11 authors N. Wolmark
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
  • 2,154
  • PDF
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
  • 99
  • PDF
...
1
2
...